MediciNova Yönetim

Yönetim kriter kontrolleri 2/4

MediciNova CEO'su Yuichi Iwaki, Jan2000 tarihinde atandı, in görev süresi 24.83 yıldır. in toplam yıllık tazminatı $ 1.39M olup, şirket hissesi ve opsiyonları dahil olmak üzere 47.4% maaş ve 52.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 2.23% ine doğrudan sahiptir ve bu hisseler ¥ 333.24M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 8.3 yıl ve 5.3 yıldır.

Anahtar bilgiler

Yuichi Iwaki

İcra Kurulu Başkanı

US$1.4m

Toplam tazminat

CEO maaş yüzdesi	47.4%
CEO görev süresi	24.8yrs
CEO sahipliği	2.2%
Yönetim ortalama görev süresi	8.3yrs
Yönetim Kurulu ortalama görev süresi	5.3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Yuichi Iwaki'un ücretlendirmesi MediciNova'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$10m
Jun 30 2024	n/a	n/a	-US$8m
Mar 31 2024	n/a	n/a	-US$8m
Dec 31 2023	US$1m	US$657k	-US$9m
Sep 30 2023	n/a	n/a	-US$10m
Jun 30 2023	n/a	n/a	-US$12m
Mar 31 2023	n/a	n/a	-US$14m
Dec 31 2022	US$1m	US$620k	-US$14m
Sep 30 2022	n/a	n/a	-US$13m
Jun 30 2022	n/a	n/a	-US$13m
Mar 31 2022	n/a	n/a	-US$13m
Dec 31 2021	US$3m	US$596k	-US$10m
Sep 30 2021	n/a	n/a	-US$11m
Jun 30 2021	n/a	n/a	-US$11m
Mar 31 2021	n/a	n/a	-US$11m
Dec 31 2020	US$3m	US$587k	-US$14m
Sep 30 2020	n/a	n/a	-US$13m
Jun 30 2020	n/a	n/a	-US$12m
Mar 31 2020	n/a	n/a	-US$11m
Dec 31 2019	US$4m	US$572k	-US$13m
Sep 30 2019	n/a	n/a	-US$11m
Jun 30 2019	n/a	n/a	-US$16m
Mar 31 2019	n/a	n/a	-US$15m
Dec 31 2018	US$3m	US$551k	-US$15m
Sep 30 2018	n/a	n/a	-US$16m
Jun 30 2018	n/a	n/a	-US$13m
Mar 31 2018	n/a	n/a	-US$13m
Dec 31 2017	US$3m	US$534k	-US$11m

Tazminat ve Piyasa: Yuichi 'nin toplam tazminatı ($USD 1.39M ), JP pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 921.46K ).

Tazminat ve Kazançlar: Yuichi şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Yuichi Iwaki (74 yo)

24.8yrs

Görev süresi

US$1,388,309

Tazminat

Dr. Yuichi Iwaki, M.D., Ph D., is a Co-Founder of MediciNova Inc. and has been its Chief Executive Officer and President since March 2006. Dr. Iwaki served as Acting Principal Financial Officer at MediciNo...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yuichi Iwaki	Co-Founder	24.8yrs	US$1.39m	2.23% ¥ 331.6m
Kazuko Matsuda	Chief Medical Officer & Director	13.2yrs	US$1.01m	0.66% ¥ 98.1m
Jason Kruger	CFO & Principal Financial Officer	2.4yrs	Veri yok	Veri yok
David Crean	Chief Business Officer	3.5yrs	Veri yok	Veri yok
John O'Neil	Controller	no data	Veri yok	Veri yok

8.3yrs

Ortalama Görev Süresi

58.5yo

Ortalama Yaş

Deneyimli Yönetim: 4875 'un yönetim ekibi deneyimli ve deneyimlidir ( 8.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yuichi Iwaki	Co-Founder	24.2yrs	US$1.39m	2.23% ¥ 331.6m
Kazuko Matsuda	Chief Medical Officer & Director	5.3yrs	US$1.01m	0.66% ¥ 98.1m
Hideki Nagao	Independent Director	7yrs	US$69.23k	0% ¥ 0
Carolyn Beaver	Independent Director	4.1yrs	US$69.23k	0% ¥ 0
Nicole Lemerond	Independent Director	1.3yrs	US$46.16k	0% ¥ 0

5.3yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 4875 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.3 yıldır).

MediciNova Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

MediciNova, Inc., Annual General Meeting, Jun 11, 2024

Less than half of directors are independent

Independent Director recently sold JP¥95k worth of stock

MediciNova, Inc. Announces Executive Changes

Independent Director recently sold JP¥1.9m worth of stock

Independent Director recently sold JP¥610k worth of stock

Recent updates

Medicinova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

MediciNova, Inc. to Report Q3, 2024 Results on Nov 14, 2024

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

MediciNova, Inc. Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition

MediciNova, Inc. to Report Q2, 2024 Results on Aug 09, 2024

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer

MediciNova, Inc. Announces Data from Phase 1B/2A Clinical Trial of Mn-166 (Ibudilast) in Glioblastoma Patients At the American Society of Clinical Oncology (Asco) Annual Meeting 2024

MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome

MediciNova, Inc. Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)

MediciNova, Inc., Annual General Meeting, Jun 11, 2024

MediciNova, Inc. to Report Q1, 2024 Results on May 10, 2024

MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan

Medicinova Announces New Data and Results of Mn-166 (Ibudilast) in Chlorine Gas-Induced Acute Lung Injury Presented At the 63Rd Annual Meeting of the Society of Toxicology

MediciNova, Inc. to Report Fiscal Year 2023 Results on Feb 14, 2024

MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China

MediciNova, Inc. Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-Induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology

MediciNova, Inc. Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe

MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada

MediciNova, Inc. to Report Q3, 2023 Results on Nov 10, 2023

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology

MediciNova, Inc. Receives A Notice of Intention to Grant for A New Patent Covering MN-166 (Ibudilast) for the Treatment of Macular Injury in Europe

Less than half of directors are independent

MediciNova, Inc. Announces Presentation of Results from the Phase 2B Trial of Mn-166 (Ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting

MediciNova Announces Health Canada Grants Authorization to Commence Multi-Arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID

MediciNova, Inc. Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder

MediciNova, Inc. Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma

MediciNova Receives Notice of Allowance for A New Patent Covering Mn-001 and Mn-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada

MediciNova, Inc. Receives Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Brazil

MediciNova, Inc. Completes Phase I Clinical Trial to Evaluate MN-166 10 MG Intravenous Infusion in Healthy Volunteers

MediciNova, Inc. Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presents at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation

Independent Director recently sold JP¥95k worth of stock

MediciNova, Inc. to Report Q3, 2022 Results on Nov 11, 2022

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Canada

First half 2022 earnings released

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Korea

MediciNova, Inc Announces Initiation of a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia

MediciNova, Inc. to Report Q2, 2022 Results on Aug 12, 2022

MediciNova, Inc. Initiates Clinical Evaluation of a New Parenteral Formulation of MN-166 (ibudilast)

MediciNova, Inc. Announces Executive Changes

MediciNova, Inc. Announces Positive Top-Line Results from Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome

Price target decreased to JP¥1,100

MediciNova, Inc. to Report Q1, 2022 Results on May 13, 2022

MediciNova, Inc. Announces Publication of MN-166 (ibudilast) Data regarding Prevention of Metastasis in Uveal Melanoma in Molecular Cancer Research

MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome

MediciNova, Inc. Announces Plans for A Phase 2 Trial of Mn-001 (Tipelukast) in Nafld with Type 2 Diabetes Mellitus and Hypertriglyceridemia

MediciNova, Inc. Announces Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Alcoholism: Clinical and Experimental Research

MediciNova, Inc. announces MN-166 (ibudilast) Identified as Promising Pharmacotherapy for Alcohol Use Disorder in Drugs

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Canada

MediciNova Receives Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Alcohol Use Disorder in Europe

MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of ALS

MediciNova, Inc. Announces MN-166 (ibudilast) Poster Presentation at the 32nd International Symposium on ALS/MND

Medicinova, Inc. Announces New Data Regarding Mn-166 (ibudilast) in Glioblastoma Presented At the 26Th Annual Meeting of the Society for Neuro-Oncology

MediciNova, Inc. Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 32nd International Symposium on ALS/MND

Chief Financial Officer Edward Stepanow has left the company

MediciNova, Inc.(NasdaqGM:MNOV) dropped from Russell 3000 Growth Index

MediciNova, Inc. Announces Positive Results from Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Nature’s Translational Psychiatry Journal

MediciNova Initiates Sheep Study under Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

Forecast breakeven pushed back to 2024

MediciNova, Inc. a Notice of Intention to Grant for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Europe

Independent Director recently sold JP¥1.9m worth of stock

New 90-day high: JP¥798

MediciNova, Inc. Announces Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-Induced Lung Injury

MediciNova, Inc. Announces Update on SARS-CoV-2 Vaccine for Covid-19

New 90-day high: JP¥670

MediciNova, Inc. announced that it has received $19.999999 million in funding from 3D Investment Partners Pte. Ltd

MediciNova, Inc. Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (Ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis in Japan

MediciNova, Inc. announced that it expects to receive $19.999999 million in funding from 3D Investment Partners Pte. Ltd

Medicinova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS

New 90-day low: JP¥456